Onconic Therapeutics Inc
476060
Company Profile
Business description
Onconic Therapeutics Inc is a company that researches and develops new drugs for gastrointestinal diseases and anticancers, which have large unmet medical needs. Its pipeline products are Zataprazan(OCN-101) and OCN-201.
Contact
12 Teheran-ro 26-gil
11th floor, Jeil Vision Tower
Gangnam-gu
Seoul06236
KORT: +82 234540780
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
29
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,010.10 | 117.10 | -1.28% |
| CAC 40 | 7,727.37 | 73.12 | 0.96% |
| DAX 40 | 23,667.32 | 179.99 | 0.77% |
| Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
| FTSE 100 | 9,164.75 | 48.06 | 0.53% |
| HKSE | 25,343.43 | 153.12 | -0.60% |
| NASDAQ | 21,279.63 | 175.92 | -0.82% |
| Nikkei 225 | 41,938.89 | 371.60 | -0.88% |
| NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
| S&P 500 | 6,415.54 | 44.72 | -0.69% |
| S&P/ASX 200 | 8,738.80 | 120.20 | -1.36% |
| SSE Composite Index | 3,813.56 | 44.58 | -1.16% |